Livedoid vasculopathy is a rare chronic-recurrent thrombo-occlusive cutaneous vasculopathy of the dermal microcirculation. It is distinguished from primary inflammatory vasculitis by dermal vessel occlusion, fibrin deposition, thrombosis, segmental hyalinization, and endothelial proliferation, producing painful lower-extremity ulcers that heal with porcelain-white atrophic scars known as atrophie blanche.
Ask a research question about Livedoid vasculopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Livedoid vasculopathy
creation_date: "2026-05-05T20:46:40Z"
updated_date: "2026-05-05T22:04:43Z"
category: Complex
description: >-
Livedoid vasculopathy is a rare chronic-recurrent thrombo-occlusive cutaneous
vasculopathy of the dermal microcirculation. It is distinguished from primary
inflammatory vasculitis by dermal vessel occlusion, fibrin deposition,
thrombosis, segmental hyalinization, and endothelial proliferation, producing
painful lower-extremity ulcers that heal with porcelain-white atrophic scars
known as atrophie blanche.
disease_term:
preferred_term: livedoid vasculopathy
term:
id: MONDO:0025514
label: livedoid vasculopathy
synonyms:
- Livedoid vasculitis
- Livedo vasculopathy
- Segmental hyalinizing vasculitis
parents:
- Vasculopathy
- Dermatologic Disease
definitions:
- name: Thrombo-occlusive dermal vasculopathy definition
definition_type: CASE_DEFINITION
description: >-
Livedoid vasculopathy is defined as a thrombo-occlusive disorder involving
dermal vessels, with clinicopathologic correlation required to separate it
from vasculitis mimics.
scope: Clinical and histopathologic recognition of livedoid vasculopathy
evidence:
- reference: DOI:10.3389/fmed.2022.993515
reference_title: >-
A comprehensive review on pathogenesis, associations, clinical findings,
and treatment of livedoid vasculopathy
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Livedoid vasculopathy (LV) is a thrombo-occlusive vasculopathy that
involves the dermal vessels.
explanation: >-
This review abstract directly defines LV as thrombo-occlusive dermal
vasculopathy.
progression:
- phase: Chronic recurrent ulceration and scarring
age_range: Adolescence to adulthood, often middle adulthood
notes: >-
Disease course is chronic and recurrent, with painful lower-extremity
ulceration followed by atrophie blanche scarring and recurrent flares.
evidence:
- reference: DOI:10.3389/fmed.2022.1012178
reference_title: Livedoid vasculopathy – A diagnostic and therapeutic challenge
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Livedoid vasculopathy is a rare, chronic-recurrent occlusive disorder in
the microcirculation of dermal vessels.
explanation: >-
This supports a chronic recurrent occlusive disease course.
pathophysiology:
- name: Dermal microvascular thrombosis
description: >-
Occlusion and thrombosis of dermal vessels create local ischemia and drive
the painful ulceration and atrophic scarring that characterize LV.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
locations:
- preferred_term: dermis
term:
id: UBERON:0002067
label: dermis
biological_processes:
- preferred_term: blood coagulation
term:
id: GO:0007596
label: blood coagulation
modifier: INCREASED
evidence:
- reference: DOI:10.3389/fmed.2022.993515
reference_title: >-
A comprehensive review on pathogenesis, associations, clinical findings,
and treatment of livedoid vasculopathy
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Histopathologically, it shows intraluminal fibrin deposition and
thrombosis, segmental hyalinization, and endothelial proliferation.
explanation: >-
This directly supports thrombosis and fibrin deposition in dermal vessels
as central tissue pathology.
downstream:
- target: Painful lower-extremity ulcers
description: Dermal vessel occlusion reduces tissue perfusion and causes painful lower-extremity ulcers.
causal_link_type: DIRECT
evidence:
- reference: DOI:10.3389/fmed.2022.993515
reference_title: >-
A comprehensive review on pathogenesis, associations, clinical findings,
and treatment of livedoid vasculopathy
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Clinically, it is characterized by the presence of painful purpuric
ulcers on the lower extremities.
explanation: >-
This links the thrombo-occlusive disease to its major lower-extremity
ulcer phenotype.
- name: Hypercoagulability and impaired fibrinolysis
description: >-
LV is associated with inherited or acquired thrombophilias and impaired
fibrinolysis. Elevated homocysteine, lipoprotein(a), and PAI-1 abnormalities
support a prothrombotic milieu in a subset of patients.
biological_processes:
- preferred_term: blood coagulation
term:
id: GO:0007596
label: blood coagulation
modifier: INCREASED
- preferred_term: fibrinolysis
term:
id: GO:0042730
label: fibrinolysis
modifier: DECREASED
evidence:
- reference: DOI:10.1111/jdv.15639
reference_title: >-
Characteristics, risk factors and treatment reality in livedoid
vasculopathy – a multicentre analysis
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Analysis of 27 patients revealed that LV patients had an increased Body
Mass Index (BMI; 11/27), hypertension (19/27) and increased levels of
lipoprotein (a) (5/12) and homocysteine (10/12) in the blood.
explanation: >-
This cohort supports common prothrombotic or vascular risk abnormalities in
LV patients.
- reference: DOI:10.1111/iwj.13480
reference_title: >-
Plasminogen activator inhibitor-1: a potential etiological role in
livedoid vasculopathy
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Enhanced expression and genotype polymorphism of PAI-1 have been observed
in LV patients.
explanation: >-
PAI-1 abnormalities support impaired fibrinolysis as a plausible mechanism,
but the review frames this as a potential etiologic role rather than a
universal cause.
downstream:
- target: Dermal microvascular thrombosis
description: >-
Inherited or acquired hypercoagulability and impaired fibrinolysis can
favor dermal microvascular occlusion and fibrin thrombosis.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: DOI:10.3389/fmed.2022.1012178
reference_title: Livedoid vasculopathy – A diagnostic and therapeutic challenge
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Different conditions that can promote a hypercoagulable state, such as
inherited and acquired thrombophilias, autoimmune connective-tissue
diseases and neoplasms, can be associated with livedoid vasculopathy.
explanation: >-
This links hypercoagulable states with livedoid vasculopathy and
supports an upstream relationship to thrombo-occlusive pathology.
phenotypes:
- name: Painful lower-extremity ulcers
category: Dermatologic
diagnostic: true
description: >-
Painful purpuric ulcers most often affect the lower legs, ankles, and feet.
phenotype_term:
preferred_term: Skin ulcer
term:
id: HP:0200042
label: Skin ulcer
evidence:
- reference: DOI:10.3389/fmed.2022.993515
reference_title: >-
A comprehensive review on pathogenesis, associations, clinical findings,
and treatment of livedoid vasculopathy
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Clinically, it is characterized by the presence of painful purpuric ulcers
on the lower extremities.
explanation: >-
This directly supports painful lower-extremity ulcers as a core phenotype.
- name: Atrophie blanche
category: Dermatologic
diagnostic: true
description: >-
Healing ulcers leave porcelain-white atrophic scars, classically termed
atrophie blanche.
phenotype_term:
preferred_term: Atrophic scars
term:
id: HP:0001075
label: Atrophic scars
evidence:
- reference: DOI:10.3389/fmed.2022.1012178
reference_title: Livedoid vasculopathy – A diagnostic and therapeutic challenge
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The clinical appearance is characterized by Livedo racemosa, painful
ulceration, located in the distal parts of the lower extremities, followed
by healing as porcelain-white, atrophic scars, the so-called Atrophie
blanche.
explanation: >-
This directly supports atrophie blanche as the characteristic healing scar.
- name: Livedo racemosa
category: Dermatologic
diagnostic: true
description: >-
Livedo racemosa or livedo-pattern violaceous discoloration commonly
accompanies ulceration.
phenotype_term:
preferred_term: Livedo reticularis
term:
id: HP:0033505
label: Livedo reticularis
evidence:
- reference: DOI:10.1111/jdv.15639
reference_title: >-
Characteristics, risk factors and treatment reality in livedoid
vasculopathy – a multicentre analysis
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Investigation of the clinical appearance found that 82% of patients had
livedo racemosa, and the ankle region was most likely to be affected by
ulceration (56–70%).
explanation: >-
This supports livedo racemosa as a common dermatologic finding.
- name: Severe pain
category: Neurologic
description: >-
Pain is a major symptom of active ulcerative LV and can substantially impair
walking, daily life, and quality of life.
phenotype_term:
preferred_term: Pain
term:
id: HP:0012531
label: Pain
evidence:
- reference: PMID:35634570
reference_title: >-
Efficacy and safety of intravenous immunoglobulin for treating refractory
livedoid vasculopathy: a systematic review.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The effective rate of IVIG therapy in LV patients was 95% (76/80) in
published studies, showing a good clinical response for resolution of pain,
skin ulcerations, and neurological symptoms, and reducing the dependence on
glucocorticoids and immunosuppressive agents.
explanation: >-
This systematic review identifies pain as a treatment-responsive symptom
in refractory LV.
histopathology:
- name: Fibrin thrombi with segmental hyalinization
diagnostic: true
description: >-
Skin biopsy shows intraluminal fibrin deposition and thrombosis, segmental
hyalinization, and endothelial proliferation, supporting a thrombo-occlusive
vasculopathy rather than primary inflammatory vasculitis.
evidence:
- reference: DOI:10.3389/fmed.2022.993515
reference_title: >-
A comprehensive review on pathogenesis, associations, clinical findings,
and treatment of livedoid vasculopathy
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Histopathologically, it shows intraluminal fibrin deposition and
thrombosis, segmental hyalinization, and endothelial proliferation.
explanation: >-
This provides the diagnostic histopathologic triad of LV.
biochemical:
- name: Elevated homocysteine and lipoprotein(a)
presence: Increased in a subset of patients
evidence:
- reference: DOI:10.1111/jdv.15639
reference_title: >-
Characteristics, risk factors and treatment reality in livedoid
vasculopathy – a multicentre analysis
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Analysis of 27 patients revealed that LV patients had an increased Body
Mass Index (BMI; 11/27), hypertension (19/27) and increased levels of
lipoprotein (a) (5/12) and homocysteine (10/12) in the blood.
explanation: >-
This cohort identifies elevated homocysteine and lipoprotein(a) in tested
LV patients.
- name: Plasminogen activator inhibitor-1 abnormality
presence: Increased expression or genotype polymorphism reported
evidence:
- reference: DOI:10.1111/iwj.13480
reference_title: >-
Plasminogen activator inhibitor-1: a potential etiological role in
livedoid vasculopathy
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Plasminogen activator inhibitor (PAI)-1 is a primary inhibitory component
of the endogenous fibrinolytic system in blood coagulation.
explanation: >-
This supports PAI-1 as a fibrinolysis regulator relevant to LV
pathophysiology.
genetic:
- name: SERPINE1 PAI-1 susceptibility signal
association: >-
Reported susceptibility association through PAI-1 expression or promoter
polymorphism affecting fibrinolysis; not a Mendelian causal gene for LV.
relationship_type: SUSCEPTIBILITY
presence: Reported in subset
notes: >-
PAI-1 is encoded by SERPINE1. Reported PAI-1 genotype polymorphism is best
modeled as a thrombophilia-associated susceptibility factor rather than a
monogenic causal allele for LV.
gene_term:
preferred_term: SERPINE1
term:
id: hgnc:8583
label: SERPINE1
evidence:
- reference: DOI:10.1111/iwj.13480
reference_title: >-
Plasminogen activator inhibitor-1: a potential etiological role in
livedoid vasculopathy
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Enhanced expression and genotype polymorphism of PAI-1 have been observed
in LV patients.
explanation: >-
This review supports SERPINE1/PAI-1 abnormalities as a reported
susceptibility mechanism in LV.
- name: F5 Factor V Leiden susceptibility signal
association: >-
Factor V Leiden is a reported thrombophilia association studied in LV-like
livedo vasculitis cohorts; this is a susceptibility signal rather than a
disease-defining cause.
relationship_type: SUSCEPTIBILITY
gene_term:
preferred_term: F5
term:
id: hgnc:3542
label: F5
evidence:
- reference: clinicaltrials:NCT00975871
reference_title: Correlation of Genetic Polymorphism and Livedo Vasculitis
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
It has been reported to be associated with some gene mutations, for
example, factor V Leiden gene.
explanation: >-
This registry summary supports Factor V Leiden as a reported association
evaluated in livedo vasculitis/LV-like patients, but not as a sufficient
causal gene.
environmental: []
epidemiology:
- name: Female-predominant adult cohort pattern
description: >-
A multicentre LV cohort showed female predominance and median age in the
early fifties.
evidence:
- reference: DOI:10.1111/jdv.15639
reference_title: >-
Characteristics, risk factors and treatment reality in livedoid
vasculopathy – a multicentre analysis
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The female‐to‐male ratio was 2.1 : 1, and the median age was 53.0 years
[interquartile range (IQR) 40.5–68].
explanation: >-
This provides cohort-level demographic context for LV.
treatments:
- name: Anticoagulant pharmacotherapy
description: >-
Anticoagulant treatment, including heparin or direct oral anticoagulants such
as rivaroxaban, is the most consistently supported pharmacologic approach
for LV in cohort and review evidence.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: rivaroxaban
term:
id: CHEBI:68579
label: rivaroxaban
- preferred_term: heparin
term:
id: CHEBI:28304
label: heparin
evidence:
- reference: DOI:10.1111/jdv.15639
reference_title: >-
Characteristics, risk factors and treatment reality in livedoid
vasculopathy – a multicentre analysis
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The analysis of patient treatment history showed that heparin was most
effective (12/17), while anti-inflammatory regimens were, although often
used (17/24), not effective (0/17).
explanation: >-
This multicentre analysis supports anticoagulation over anti-inflammatory
regimens in clinical practice.
- reference: DOI:10.3389/fmed.2022.993515
reference_title: >-
A comprehensive review on pathogenesis, associations, clinical findings,
and treatment of livedoid vasculopathy
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Among them, pain management, wound care, control of cardiovascular risk
factors, and both antiplatelets and anticoagulants, mostly rivaroxaban, are
the main therapies used.
explanation: >-
This review supports antiplatelet and anticoagulant therapy, especially
rivaroxaban, as commonly used management.
- name: Wound care and pain management
description: >-
Supportive care targets painful ulcerations, wound healing, cardiovascular
risk-factor control, and preservation of quality of life.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: DOI:10.3389/fmed.2022.993515
reference_title: >-
A comprehensive review on pathogenesis, associations, clinical findings,
and treatment of livedoid vasculopathy
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Among them, pain management, wound care, control of cardiovascular risk
factors, and both antiplatelets and anticoagulants, mostly rivaroxaban, are
the main therapies used.
explanation: >-
This review identifies pain management and wound care as central supportive
management components.
- name: Intravenous immunoglobulin for refractory disease
description: >-
IVIG has been reported as a treatment alternative for refractory LV, with
published cases showing improvement in pain, ulcerations, and neurologic
symptoms; randomized evidence remains lacking.
treatment_term:
preferred_term: immunoglobulin infusion therapy
term:
id: MAXO:0001480
label: immunoglobulin infusion therapy
evidence:
- reference: PMID:35634570
reference_title: >-
Efficacy and safety of intravenous immunoglobulin for treating refractory
livedoid vasculopathy: a systematic review.
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Overall, to a certain degree, IVIG is probably a safe and effective
treatment alternative for refractory LV patients, which still need to be
confirmed by large-scale randomized controlled clinical trials.
explanation: >-
This systematic review supports IVIG as a refractory-disease option but
explicitly notes the need for stronger randomized evidence.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Livedoid vasculopathy covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Livedoid vasculopathy (LV) is currently best understood as a noninflammatory thrombotic/occlusive microvascular disorder of dermal vessels that causes ischemia-driven, painful lower-extremity ulceration and scarring, rather than a primary inflammatory vasculitis. Diagnostic confirmation typically requires clinicopathologic correlation, because superficial sampling or sampling older lesions may be nondiagnostic. Antithrombotic therapy (LMWH or DOACs, especially rivaroxaban) is the most consistently supported treatment approach in contemporary reviews and real-world cohorts; escalation strategies include prostanoids (e.g., iloprost) and IVIG for refractory disease. (alavi2013livedoidvasculopathyan pages 1-2, alavi2013livedoidvasculopathyan pages 5-7, burg2022livedoidvasculopathy– pages 1-2, burg2022livedoidvasculopathy– media d7cd3b46)
| Domain | Key findings | Quantitative data | Evidence type | Key citation (year) |
|---|---|---|---|---|
| Definition & synonyms | Livedoid vasculopathy (LV) is a rare, chronic, relapsing noninflammatory thrombotic/occlusive dermal vasculopathy of the lower extremities; distinct from inflammatory vasculitis. Historical/alternative names include livedoid vasculitis, segmental hyalinizing vasculitis, livedo reticularis with summer ulcerations, and association with but distinction from atrophie blanche (a morphologic scar pattern, not a synonym for all cases). (alavi2013livedoidvasculopathyan pages 1-2, burg2022livedoidvasculopathy– pages 1-2, leeolou2023livedoidvasculopathy pages 1-3) | Rare disease; incidence commonly cited at about 1 per 100,000. (segui2022acomprehensivereview pages 1-2) | Modified Delphi consensus, review, case review | Alavi et al., J Am Acad Dermatol 2013, DOI: 10.1016/j.jaad.2013.07.019; Burg et al., Front Med 2022, DOI: 10.3389/fmed.2022.1012178; Leeolou et al., Dermatol Online J 2023, DOI: 10.5070/d329562414 |
| Key clinicopathologic triad | Characteristic clinical triad: livedo racemosa/reticular violaceous pattern + painful small punched-out ulcers + porcelain-white stellate atrophic scars (atrophie blanche), usually around ankles/dorsal feet/lower legs. (jatana2025livedoidvasculopathy pages 7-8, segui2022acomprehensivereview pages 2-4, burg2022livedoidvasculopathy– pages 1-2) | Livedo racemosa reported in 82% in one multicentre cohort and 85% in one reviewed study. (weishaupt2019characteristicsriskfactors pages 6-7, segui2022acomprehensivereview pages 2-4) | Multicentre cohort, review | Weishaupt et al., JEADV 2019, DOI: 10.1111/jdv.15639; Seguí & Llamas-Velasco, Front Med 2022, DOI: 10.3389/fmed.2022.993515 |
| Histology / biopsy | Typical biopsy shows intraluminal fibrin thrombi/thrombosis, segmental hyalinization/subintimal hyaline degeneration, endothelial proliferation, vessel-wall thickening, RBC extravasation, and minimal or absent vasculitic inflammation/leukocytoclasia. Deep biopsy including ulcer margin and adjacent skin/subcutis is recommended; multiple biopsies may be needed because lesions are segmental. (alavi2013livedoidvasculopathyan pages 5-7, burg2022livedoidvasculopathy– pages 6-8, criado2011livedoidvasculopathyas pages 4-5) | No single validated diagnostic score; biopsy often needed before systemic therapy. (burg2022livedoidvasculopathy– pages 6-8, qi2024identificationofchallenging pages 2-4) | Delphi consensus, review, retrospective study | Alavi et al., J Am Acad Dermatol 2013, DOI: 10.1016/j.jaad.2013.07.019; Burg et al., Front Med 2022, DOI: 10.3389/fmed.2022.1012178; Qi et al., Clin Cosmet Investig Dermatol 2024, DOI: 10.2147/CCID.S466449 |
| Epidemiology | LV is uncommon with female predominance and mainly affects adolescents to middle-aged adults, though older adults are also represented. (segui2022acomprehensivereview pages 1-2, weishaupt2019characteristicsriskfactors pages 6-7, lee2020livedoidvasculopathyin pages 5-7) | Incidence ~1/100,000; female:male ratio reported as 3:1 in reviews, 2.1:1 in a multicentre cohort, and 29:11 in a Korean cohort; median age 53 y (IQR 40.5–68) in one multicentre cohort; onset age 33 y (range 12–65) in Korean cohort. (segui2022acomprehensivereview pages 1-2, weishaupt2019characteristicsriskfactors pages 6-7, lee2020livedoidvasculopathyin pages 5-7) | Review, multicentre cohort, cohort | Seguí & Llamas-Velasco 2022, DOI: 10.3389/fmed.2022.993515; Weishaupt et al. 2019, DOI: 10.1111/jdv.15639; Lee & Cho 2020, DOI: 10.1111/jdv.16129 |
| Diagnostic delay / misdiagnosis | Diagnosis is frequently delayed and patients are commonly misdiagnosed as vasculitis or eczema-like disorders; clinicopathologic correlation is essential. (qi2024identificationofchallenging pages 2-4, evans2015successfultreatmentof pages 2-2) | Mean diagnostic delay about 5 years in reviews; 4.61 ± 0.69 years in a 2024 retrospective study; 85.18% (23/27) had an alternate prior diagnosis and 73.9% (17/23) of delayed cases had been labeled allergic vasculitis. (segui2022acomprehensivereview pages 1-2, qi2024identificationofchallenging pages 2-4) | Review, retrospective cohort | Qi et al., Clin Cosmet Investig Dermatol 2024, DOI: 10.2147/CCID.S466449; Seguí & Llamas-Velasco 2022, DOI: 10.3389/fmed.2022.993515 |
| Risk factors / associations: thrombophilia | LV is associated with inherited/acquired prothrombotic states including Factor V Leiden, prothrombin G20210A, protein C/S or antithrombin abnormalities, antiphospholipid antibodies, hyperhomocysteinemia, lipoprotein(a) elevation, and PAI-1/SERPINE1-related impaired fibrinolysis. (criado2011livedoidvasculopathyas pages 2-3, segui2022acomprehensivereview pages 1-2, gao2020plasminogenactivatorinhibitor‐1 pages 1-3) | Abnormal procoagulant parameters in 44% (11/25) in one cohort and 42.5% (17/40) in a Korean cohort; prospective series 52% (18/34) with thrombophilia; antiphospholipid antibodies 17.64%, Factor V Leiden 17.64%, protein C/S deficiency 8.82% in one series; homocysteine elevated in 10/12 (83%) and lipoprotein(a) in 5/12 (42%) in a multicentre cohort. (weishaupt2019characteristicsriskfactors pages 2-4, lee2020livedoidvasculopathyin pages 5-7, segui2022acomprehensivereview pages 1-2) | Cohort, review | Weishaupt et al. 2019, DOI: 10.1111/jdv.15639; Lee & Cho 2020, DOI: 10.1111/jdv.16129; Seguí & Llamas-Velasco 2022, DOI: 10.3389/fmed.2022.993515; Criado et al. 2011, DOI: 10.1016/j.autrev.2010.11.008 |
| Risk factors / associations: PAI-1 and fibrinolysis | Impaired fibrinolysis is a leading mechanistic model. PAI-1/SERPINE1 overexpression and promoter polymorphisms (especially 4G/5G, sometimes 4G/4G) have been repeatedly reported; PAI-1 localizes to lesional extracellular matrix/perivascular tissue. (agirbasli2011enhancedfunctionalstability pages 4-5, gao2020plasminogenactivatorinhibitor‐1 pages 1-3, agirbasli2011enhancedfunctionalstability pages 2-4) | In 20 biopsy-proven LV cases, median PAI-1 antigen 34 vs 17 ng/mL in controls (P < 0.01); residual PAI-1 activity after 16 h was detectable in LV but absent in controls, indicating markedly enhanced stability. PAI-1 4G/5G genotype distribution: 20% 5G/5G, 55% 4G/5G, 25% 4G/4G in that cohort; a systematic review cited PAI-1 675 4G/5G in 85.26% of reported genetically studied cases. (agirbasli2011enhancedfunctionalstability pages 2-4, segui2022acomprehensivereview pages 1-2) | Case-control mechanistic study, review | Agirbasli et al., J Thromb Thrombolysis 2011, DOI: 10.1007/s11239-011-0556-y; Gao & Jin, Int Wound J 2020, DOI: 10.1111/iwj.13480; Seguí & Llamas-Velasco 2022, DOI: 10.3389/fmed.2022.993515 |
| Risk factors / associations: comorbidities | Reported associated conditions include autoimmune/connective tissue disease, cryoglobulinemia, venous insufficiency, polycythemia vera, and thromboembolic events; hypertension and elevated BMI are common in adult cohorts. (weishaupt2019characteristicsriskfactors pages 6-7, lee2020livedoidvasculopathyin pages 5-7, burg2022livedoidvasculopathy– pages 1-2) | Hypertension in 70% and elevated BMI in about 40% of one multicentre cohort; deep vein thrombosis in 11% (3/27); venous insufficiency 7.5% (3/40) and polycythemia vera 2.5% (1/40) in a Korean cohort. (weishaupt2019characteristicsriskfactors pages 6-7, weishaupt2019characteristicsriskfactors pages 2-4, lee2020livedoidvasculopathyin pages 5-7) | Multicentre cohort, cohort | Weishaupt et al. 2019, DOI: 10.1111/jdv.15639; Lee & Cho 2020, DOI: 10.1111/jdv.16129 |
| First-line treatment: anticoagulation / DOACs | Best-supported current therapy is anticoagulation, especially rivaroxaban or LMWH; antiplatelets and supportive wound/pain care are often adjunctive. Reviews and algorithms place LMWH/DOACs as first-line, with escalation to iloprost or IVIG for refractory disease. (burg2022livedoidvasculopathy– pages 1-2, burg2022livedoidvasculopathy– media d7cd3b46, leeolou2023livedoidvasculopathy pages 1-3) | In a phase 2a single-arm rivaroxaban study of 25 patients, 95% had clinically significant pain reduction; 44% had confirmed hypercoagulability abnormalities, with no apparent efficacy difference by thrombophilia status. In a review of 73 patients, 82.2% (60/73) improved on rivaroxaban. (leeolou2023livedoidvasculopathy pages 3-4) | Phase 2a single-arm trial; review/case aggregation | Leeolou et al. 2023 summarizing RILIVA and pooled data, DOI: 10.5070/d329562414; Burg et al. 2022, DOI: 10.3389/fmed.2022.1012178 |
| Real-world treatment effectiveness | In practice, anticoagulants outperform anti-inflammatory regimens; steroids are commonly tried before diagnosis but often ineffective. (weishaupt2019characteristicsriskfactors pages 1-2, qi2024identificationofchallenging pages 2-4) | In multicentre prestudy treatment data, heparin was rated good/very good in 12/17 (71%); rivaroxaban 2/2 (100%) in a very small subset; NSAIDs 1/9 (11%); anti-inflammatory regimens had 0/17 effectiveness among exposed patients. Before final diagnosis, 65.21% received systemic corticosteroids in one 2024 cohort. (weishaupt2019characteristicsriskfactors pages 4-5, qi2024identificationofchallenging pages 2-4) | Multicentre cohort; retrospective cohort | Weishaupt et al. 2019, DOI: 10.1111/jdv.15639; Qi et al. 2024, DOI: 10.2147/CCID.S466449 |
| IVIG and refractory-disease options | IVIG is commonly used for refractory LV, especially with severe pain or neuropathy; case-series/systematic-review evidence suggests benefit, but high-quality comparative trials are lacking. Hyperbaric oxygen, TNF inhibitors, JAK inhibitors, sulodexide, and prostanoids/iloprost are reported for difficult cases. (palanisamy2023painmanagementoptions pages 3-3, jatana2025livedoidvasculopathy pages 7-8, ramphall2022comparativeefficacyof pages 9-9) | Quantitative IVIG efficacy figures were not provided in the available excerpts; anti-TNF evidence includes 34.3% pain reduction after 12 weeks with etanercept in a cited report. A hyperbaric oxygen study enrolled 12 patients with active idiopathic LV (details not extracted here). (palanisamy2023painmanagementoptions pages 3-3) | Systematic review, case series, case reports | Palanisamy et al., EJCRIM 2023, DOI: 10.12890/2023_003727; Ramphall et al., Cureus 2022, DOI: 10.7759/cureus.28485; Juan et al., Br J Dermatol 2006, DOI: 10.1111/j.1365-2133.2005.06843.x |
| Supportive care / implementation | Across reviews and algorithms, management should also include wound care, pain control, smoking cessation, compression (after excluding significant arterial disease), and cardiovascular risk modification. (jatana2025livedoidvasculopathy pages 7-8, alavi2013livedoidvasculopathyan pages 5-7, burg2022livedoidvasculopathy– pages 1-2) | Compression should be considered only after arterial disease exclusion (e.g., ABPI/toe pressures); no standardized outcome percentages available in the excerpts. (alavi2013livedoidvasculopathyan pages 5-7) | Consensus/review | Alavi et al. 2013, DOI: 10.1016/j.jaad.2013.07.019; Burg et al. 2022, DOI: 10.3389/fmed.2022.1012178 |
Table: This table condenses the most clinically useful disease-characterization data for livedoid vasculopathy, including definitions, pathology, epidemiology, risk associations, and treatment outcomes. It is useful as a quick evidence map for knowledge-base curation and clinical reference.
A widely cited international modified-Delphi analysis characterizes LV as a “noninflammatory thrombotic condition” presenting with chronic recurrent reticulated purpura of the legs, painful ulcers (classically around ankles/dorsal feet), and stellate porcelain-white scars. (alavi2013livedoidvasculopathyan pages 1-2)
A 2023 peer-reviewed clinical review similarly defines LV as a rare, painful thrombo-occlusive vascular disorder with spontaneous thrombosis in medium-sized arterioles causing local hypoxia and skin ulceration. (leeolou2023livedoidvasculopathy pages 1-3)
Synonyms/related terms used in the literature include livedoid vasculitis, segmental hyalinizing vasculitis, and older usage conflating LV with atrophie blanche; however, atrophie blanche is now emphasized as a morphologic healing pattern rather than a disease-specific synonym. (alavi2013livedoidvasculopathyan pages 1-2, evans2015successfultreatmentof pages 2-2, jatana2025livedoidvasculopathy pages 7-8)
Within the retrieved full-text corpus for this run, I could not extract authoritative mappings to MONDO, Orphanet, ICD-10/ICD-11, OMIM, or MeSH IDs for LV without risking incorrect identifier assignment. This element remains not available from the provided evidence set.
Much of the therapeutic knowledge base remains derived from case reports/series and single-arm cohorts, reflecting disease rarity. The 2024 diagnostic-delay study and multicenter cohorts provide more aggregated evidence on diagnostic pitfalls and associated risk factors. (qi2024identificationofchallenging pages 2-4, weishaupt2019characteristicsriskfactors pages 6-7)
The prevailing model is that LV arises from microvascular thrombosis and impaired fibrinolysis in dermal vessels, leading to focal ischemia, ulceration, and scarring. Histology and treatment response patterns support a procoagulant/prothrombotic pathogenesis rather than immune-complex vasculitis as the primary driver. (alavi2013livedoidvasculopathyan pages 1-2, criado2011livedoidvasculopathyas pages 4-5, leeolou2023livedoidvasculopathy pages 1-3)
A 2019 multicentre cohort analysis (derived from a phase IIa rivaroxaban study cohort) reported prothrombotic abnormalities in 44% (11/25), with notably high rates among those tested for specific markers: elevated homocysteine 10/12 (83%) and elevated lipoprotein(a) 5/12 (42%). (weishaupt2019characteristicsriskfactors pages 2-4)
A Korean cohort of 40 patients reported coagulation laboratory abnormalities in 42.5% (17/40). (lee2020livedoidvasculopathyin pages 5-7)
A 2011 synthesis emphasized frequent associations reported across case series with antiphospholipid antibodies, Factor V Leiden, prothrombin G20210A, MTHFR-related hyperhomocysteinemia, and protein C/S/antithrombin abnormalities. (criado2011livedoidvasculopathyas pages 2-3)
The multicentre analysis reported hypertension in 70% and elevated BMI in ~40% (11/27) of participants, highlighting frequent coexistence of cardiovascular risk factors in adult cohorts. (weishaupt2019characteristicsriskfactors pages 2-4, weishaupt2019characteristicsriskfactors pages 6-7)
A ClinicalTrials.gov observational study explicitly designed to test whether LV has a “Strong Association With Smoking” (NCT05878327) compared smoking history and cardiovascular risk factors against the Swiss general population, with secondary thrombophilia screening. However, the registry excerpt provides design/aims rather than quantitative results. (NCT05878327 chunk 1)
No protective genetic variants or environmental protective factors were identified in the retrieved evidence set.
Direct evidence of gene–environment interaction (e.g., specific variant × smoking effect modification) was not present in the retrieved full-text corpus.
The canonical clinical triad is: 1) Livedo racemosa (persistent, broken, branched violaceous pattern), 2) Very painful small punched-out ulcers (often <1 cm), 3) Porcelain-white atrophic scars (atrophie blanche) after healing. (jatana2025livedoidvasculopathy pages 7-8, segui2022acomprehensivereview pages 2-4, burg2022livedoidvasculopathy– pages 1-2)
Frequency examples: - Livedo racemosa ~82% in a multicentre cohort. (weishaupt2019characteristicsriskfactors pages 6-7) - In one reviewed study, livedo racemosa was reported in 85%. (segui2022acomprehensivereview pages 2-4)
Distribution examples: - Korean cohort: ankle 84.2%, leg 65.8%, foot 42.1%, upper extremities 7.9%, with 97.4% bilaterality. (lee2020livedoidvasculopathyin pages 5-7)
Extracutaneous involvement was noted in 13.2% (5/38) in the Korean cohort excerpt. (lee2020livedoidvasculopathyin pages 5-7)
A diagnostic review notes thrombus formation can involve vasa nervorum, providing a mechanistic basis for neuropathic symptoms in some patients. (burg2022livedoidvasculopathy– pages 6-8)
LV is typically chronic and relapsing, with substantial diagnostic delay. Review-level estimates cite mean diagnostic delay around 5 years, and a 2024 retrospective cohort reported mean time from onset to final diagnosis of 4.61 ± 0.69 years. (segui2022acomprehensivereview pages 1-2, qi2024identificationofchallenging pages 2-4)
LV is repeatedly described as painful and functionally limiting; one recent clinical review explicitly notes its negative quality-of-life impact (painful ulcers, recurring lesions, scarring). Although QoL instruments (e.g., DLQI, SF-36) were not extractable from this evidence set, cohort descriptions and pain-focused reports emphasize severe pain burden and treatment-refractory pain in some cases. (leeolou2023livedoidvasculopathy pages 1-3, palanisamy2023painmanagementoptions pages 3-3)
(These HPO suggestions are ontology mappings; the clinical features are evidence-supported above.)
Available evidence supports LV as largely multifactorial/association-based, frequently linked to thrombophilia and impaired fibrinolysis, rather than a single-gene Mendelian disorder. (alavi2013livedoidvasculopathyan pages 1-2, segui2022acomprehensivereview pages 1-2)
Commonly reported thrombophilia-related genes/variants include: - SERPINE1 (PAI-1) promoter 4G/5G polymorphism; reviews cite high prevalence among genetically studied cases (e.g., PAI-1 675 4G/5G in 85.26% in one systematic review summarized in a 2022 review). (segui2022acomprehensivereview pages 1-2) - MTHFR polymorphisms (C677T, A1298C) and hyperhomocysteinemia associations. (gao2020plasminogenactivatorinhibitor‐1 pages 1-3, segui2022acomprehensivereview pages 1-2) - F5 (Factor V Leiden / G1691A) and F2 (Prothrombin G20210A). (criado2011livedoidvasculopathyas pages 2-3, segui2022acomprehensivereview pages 1-2) - Natural anticoagulant pathways: protein C/S and antithrombin abnormalities. (weishaupt2019characteristicsriskfactors pages 2-4, criado2011livedoidvasculopathyas pages 2-3)
ClinicalTrials.gov genetic association study (Taiwan) explicitly targeted Factor V Leiden, Prothrombin G20210A, PAI promoter 4G/4G, and MTHFR C677T in “livedo vasculitis” patients with LV-like clinicopathology and histology (fibrin deposition). (NCT00975871 chunk 1)
A mechanistic case-control study of 20 biopsy-proven LV patients reported increased antifibrinolytic signal: - Median PAI-1 antigen 34 vs 17 ng/mL in controls (P < 0.01), and detectable residual PAI-1 activity after 16 h in patients but not controls, suggesting substantially enhanced functional stability. (agirbasli2011enhancedfunctionalstability pages 2-4) This supports the concept that LV may involve suppressed plasmin generation (via PAI-1 inhibition of tPA/uPA), promoting persistent fibrin-rich microthrombi. (agirbasli2011enhancedfunctionalstability pages 2-4, gao2020plasminogenactivatorinhibitor‐1 pages 1-3)
ClinVar-based pathogenicity classifications and population allele frequencies (e.g., gnomAD) were not available from the retrieved evidence set in this run.
Direct quantitative evidence on environmental exposures was limited in the retrieved literature. Smoking has been hypothesized as important enough to motivate an observational study (NCT05878327), but results were not provided in the excerpt. (NCT05878327 chunk 1)
No infectious agent was identified as a primary trigger in the retrieved evidence set.
Upstream drivers (heterogeneous across patients): - Hypercoagulability and thrombophilia (inherited/acquired). (weishaupt2019characteristicsriskfactors pages 2-4, criado2011livedoidvasculopathyas pages 2-3) - Impaired fibrinolysis (PAI-1/SERPINE1 elevation and/or functional stabilization). (agirbasli2011enhancedfunctionalstability pages 2-4, gao2020plasminogenactivatorinhibitor‐1 pages 1-3) - Endothelial injury/dysfunction (proposed in reviews) and rheological disturbances (e.g., cryoglobulins). (jatana2025livedoidvasculopathy pages 7-8, weishaupt2019characteristicsriskfactors pages 2-4)
Intermediate steps: - Segmental dermal vessel thrombosis with fibrin deposition and subintimal hyalinization/endothelial proliferation. (alavi2013livedoidvasculopathyan pages 5-7, criado2011livedoidvasculopathyas pages 4-5)
Downstream manifestations: - Cutaneous ischemia/hypoxia → painful purpura/retiform lesions → small punched-out ulcerations → atrophie blanche scarring. (alavi2013livedoidvasculopathyan pages 1-2, segui2022acomprehensivereview pages 2-4)
Although LV is framed as noninflammatory, direct immunofluorescence may show fibrin (early) and Ig/complement deposition (later) without necessarily implying primary immune-complex vasculitis; slight perivascular leukocytes and absence of leukocytoclasia help distinguish from leukocytoclastic vasculitis. (alavi2013livedoidvasculopathyan pages 5-7, burg2022livedoidvasculopathy– pages 1-2, criado2011livedoidvasculopathyas pages 4-5)
LV primarily affects skin microvasculature of the lower extremities (malleolar region, dorsal foot, lower legs). (segui2022acomprehensivereview pages 2-4, lee2020livedoidvasculopathyin pages 5-7)
Onset spans adolescence through older adulthood. Example cohort data: - Korean cohort onset central measure 33 years (range 12–65). (lee2020livedoidvasculopathyin pages 5-7) - Multicentre cohort median age 53 years (IQR 40.5–68). (weishaupt2019characteristicsriskfactors pages 2-4)
LV generally follows a chronic, relapsing course, with recurrent ulcer episodes and residual scarring. (alavi2013livedoidvasculopathyan pages 1-2, leeolou2023livedoidvasculopathy pages 1-3)
Review-level estimates commonly cite incidence around 1 per 100,000 with female predominance (e.g., 3:1). (segui2022acomprehensivereview pages 1-2)
Multicentre and national cohorts show variable but consistent female predominance: - Female:male ≈ 2.1:1 in a multicentre cohort. (weishaupt2019characteristicsriskfactors pages 6-7) - Korean cohort: 29 female / 11 male. (lee2020livedoidvasculopathyin pages 5-7)
No evidence supports a single Mendelian inheritance for LV overall; rather, it is linked to susceptibility variants and acquired thrombophilic states. (segui2022acomprehensivereview pages 1-2, criado2011livedoidvasculopathyas pages 2-3)
Typical presentation includes painful retiform purpura/livedo racemosa with recurrent small ulcers in the lower legs/ankles/feet and atrophie blanche scarring. (alavi2013livedoidvasculopathyan pages 1-2, segui2022acomprehensivereview pages 2-4)
Core histopathologic features: - Intraluminal thrombosis/fibrin thrombi - Endothelial proliferation - Subintimal hyaline degeneration / segmental hyalinization with minimal inflammation. (alavi2013livedoidvasculopathyan pages 5-7, criado2011livedoidvasculopathyas pages 4-5)
Biopsy technique (consensus and expert guidance): - Modified-Delphi recommendations emphasize a deep 4–6 mm excisional or punch biopsy down to fascia, including ulcer margin, adjacent healthy skin, and lower subcutis, because disease is segmental and classic changes can be missed. (alavi2013livedoidvasculopathyan pages 5-7) - Practical diagnostic review recommends avoiding direct ulcer sampling and using deep excision (especially early/active lesions) to exclude deeper vasculitides (e.g., cutaneous PAN). (burg2022livedoidvasculopathy– pages 6-8)
Consensus and cohort literature supports targeted evaluation for hypercoagulable/fibrinolytic disorders and autoimmune/paraproteinemia screening as clinically indicated; however, thrombophilia testing may not always change therapy but may assist counseling or identify treatable hyperhomocysteinemia. (alavi2013livedoidvasculopathyan pages 5-7)
Misdiagnosis is common: - 2024 retrospective cohort: 85.18% had alternate diagnoses before final LV diagnosis; allergic vasculitis was common. (qi2024identificationofchallenging pages 2-4)
Differential diagnosis includes pyoderma gangrenosum, factitial dermatitis, cutaneous polyarteritis nodosa, leukocytoclastic vasculitis, pseudo-Kaposi sarcoma, Degos disease and chronic venous stasis. (jatana2025livedoidvasculopathy pages 7-8)
Morbidity is dominated by chronic pain, recurrent ulceration, and irreversible scarring. (leeolou2023livedoidvasculopathy pages 1-3, alavi2013livedoidvasculopathyan pages 1-2)
A multicentre cohort reported deep vein thrombosis in 11% (3/27), higher than general population estimates cited by the authors. (weishaupt2019characteristicsriskfactors pages 6-7)
No survival or mortality rates were available in the retrieved evidence set; LV is primarily a morbidity-driven dermatologic microvascular disorder.
Across consensus/reviews and multicentre cohorts, treatment typically combines: - Pain control - Wound care and infection prevention - Compression only after excluding significant arterial disease (e.g., ABPI/toe pressures) - Risk-factor modification (cardiovascular risks; smoking cessation commonly recommended) - Antithrombotic therapy (anticoagulation ± antiplatelets). (alavi2013livedoidvasculopathyan pages 5-7, jatana2025livedoidvasculopathy pages 7-8)
A 2023 clinical review summarizes evidence that a multicentre single-arm phase 2a study of 25 patients treated with rivaroxaban showed clinically significant pain reduction across 95% of participants, with similar benefit whether or not a known prothrombotic state was present (44% had confirmed hypercoagulability abnormalities). (leeolou2023livedoidvasculopathy pages 3-4)
The same source summarizes a review of 73 patients with LV in which 82.2% (60/73) improved with rivaroxaban. (leeolou2023livedoidvasculopathy pages 3-4)
Case-report evidence demonstrates sustained remission on rivaroxaban in recalcitrant LV, including complete healing and absence of new ulcers over months in individual patients. (evans2015successfultreatmentof pages 2-2)
In a multicentre analysis of treatment reality: - Heparin was rated good/very good by patients in 12/17 (71%). - Anti-inflammatory regimens were frequently used but had 0/17 effectiveness among exposed patients. These findings support anticoagulation as a pragmatic first-line approach. (weishaupt2019characteristicsriskfactors pages 4-5, weishaupt2019characteristicsriskfactors pages 1-2)
IVIG is commonly cited for refractory LV (especially severe pain/neuropathy), supported by systematic reviews and case series rather than large randomized trials. (palanisamy2023painmanagementoptions pages 3-3, jatana2025livedoidvasculopathy pages 7-8)
Burg et al. (Frontiers in Medicine, 2022) provide a structured algorithm placing LMWH/DOACs as first-line, iloprost as second-line, and IVIG as third-line escalation, with additional options discussed for refractory disease. (burg2022livedoidvasculopathy– media d7cd3b46)
Primary prevention strategies are not well-defined due to uncertain causality; pragmatic prevention focuses on: - Managing cardiovascular risk factors - Smoking cessation - Preventing ulcer recurrence via maintaining adequate anticoagulation in responsive patients Evidence in this set is largely inferential from risk-factor associations and treatment response patterns rather than prevention trials. (weishaupt2019characteristicsriskfactors pages 2-4, jatana2025livedoidvasculopathy pages 7-8)
No naturally occurring LV analog in non-human species was identified in the retrieved evidence set.
No established LV-specific animal model was identified in the retrieved evidence set. Mechanistic inference is sometimes supported by broader PAI-1 biology and thrombosis/fibrosis models, but LV-specific model organism resources were not captured here. (agirbasli2011enhancedfunctionalstability pages 4-5)
A 2024 retrospective cohort (Peking Union Medical College Hospital; publication Aug 2024) quantified a prolonged diagnostic delay (mean 4.61 ± 0.69 years) and high misdiagnosis burden (85.18% with alternate prior diagnoses; allergic vasculitis common), supporting current emphasis on early biopsy and clinicopathologic correlation. URL: https://doi.org/10.2147/CCID.S466449 (published 2024-08). (qi2024identificationofchallenging pages 2-4)
Contemporary reviews and algorithms continue to consolidate anticoagulation-first management, with escalation to iloprost/IVIG, reflecting convergence of cohort outcomes and expert opinion despite limited randomized trial evidence. (burg2022livedoidvasculopathy– media d7cd3b46, weishaupt2019characteristicsriskfactors pages 1-2)
References
(alavi2013livedoidvasculopathyan pages 1-2): Afsaneh Alavi, Jürg Hafner, Jan P. Dutz, Dieter Mayer, R. Gary Sibbald, Paulo Ricardo Criado, Patricia Senet, Jeffery P. Callen, Tania J. Phillips, Marco Romanelli, and Robert S. Kirsner. Livedoid vasculopathy: an in-depth analysis using a modified delphi approach. Journal of the American Academy of Dermatology, 69 6:1033-1042.e1, Dec 2013. URL: https://doi.org/10.1016/j.jaad.2013.07.019, doi:10.1016/j.jaad.2013.07.019. This article has 159 citations and is from a domain leading peer-reviewed journal.
(alavi2013livedoidvasculopathyan pages 5-7): Afsaneh Alavi, Jürg Hafner, Jan P. Dutz, Dieter Mayer, R. Gary Sibbald, Paulo Ricardo Criado, Patricia Senet, Jeffery P. Callen, Tania J. Phillips, Marco Romanelli, and Robert S. Kirsner. Livedoid vasculopathy: an in-depth analysis using a modified delphi approach. Journal of the American Academy of Dermatology, 69 6:1033-1042.e1, Dec 2013. URL: https://doi.org/10.1016/j.jaad.2013.07.019, doi:10.1016/j.jaad.2013.07.019. This article has 159 citations and is from a domain leading peer-reviewed journal.
(burg2022livedoidvasculopathy– pages 1-2): Maria Rosa Burg, Carolin Mitschang, Tobias Goerge, and Stefan Werner Schneider. Livedoid vasculopathy – a diagnostic and therapeutic challenge. Frontiers in Medicine, Oct 2022. URL: https://doi.org/10.3389/fmed.2022.1012178, doi:10.3389/fmed.2022.1012178. This article has 33 citations.
(burg2022livedoidvasculopathy– media d7cd3b46): Maria Rosa Burg, Carolin Mitschang, Tobias Goerge, and Stefan Werner Schneider. Livedoid vasculopathy – a diagnostic and therapeutic challenge. Frontiers in Medicine, Oct 2022. URL: https://doi.org/10.3389/fmed.2022.1012178, doi:10.3389/fmed.2022.1012178. This article has 33 citations.
(leeolou2023livedoidvasculopathy pages 1-3): Melissa C. Leeolou, Kerri E Rieger, and Jennifer E Yeh. Livedoid vasculopathy. Dermatology Online Journal, Nov 2023. URL: https://doi.org/10.5070/d329562414, doi:10.5070/d329562414. This article has 4 citations and is from a peer-reviewed journal.
(segui2022acomprehensivereview pages 1-2): Mireia Seguí and Mar Llamas-Velasco. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy. Frontiers in Medicine, Dec 2022. URL: https://doi.org/10.3389/fmed.2022.993515, doi:10.3389/fmed.2022.993515. This article has 21 citations.
(jatana2025livedoidvasculopathy pages 7-8): Gurpoonam Jatana. Livedoid vasculopathy. Journal of Dermatology Research, Mar 2025. URL: https://doi.org/10.46889/jdr.2025.6107, doi:10.46889/jdr.2025.6107. This article has 2 citations.
(segui2022acomprehensivereview pages 2-4): Mireia Seguí and Mar Llamas-Velasco. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy. Frontiers in Medicine, Dec 2022. URL: https://doi.org/10.3389/fmed.2022.993515, doi:10.3389/fmed.2022.993515. This article has 21 citations.
(weishaupt2019characteristicsriskfactors pages 6-7): C. Weishaupt, A. Strölin, B. Kahle, A. Kreuter, S. W. Schneider, J. Gerss, M. Eveslage, A. Drabik, and T. Goerge. Characteristics, risk factors and treatment reality in livedoid vasculopathy – a multicentre analysis. Journal of the European Academy of Dermatology and Venereology, 33:1784-1791, Sep 2019. URL: https://doi.org/10.1111/jdv.15639, doi:10.1111/jdv.15639. This article has 71 citations and is from a domain leading peer-reviewed journal.
(burg2022livedoidvasculopathy– pages 6-8): Maria Rosa Burg, Carolin Mitschang, Tobias Goerge, and Stefan Werner Schneider. Livedoid vasculopathy – a diagnostic and therapeutic challenge. Frontiers in Medicine, Oct 2022. URL: https://doi.org/10.3389/fmed.2022.1012178, doi:10.3389/fmed.2022.1012178. This article has 33 citations.
(criado2011livedoidvasculopathyas pages 4-5): Paulo Ricardo Criado, Evandro Ararigboia Rivitti, Mirian Nacagami Sotto, and Jozélio Freire de Carvalho. Livedoid vasculopathy as a coagulation disorder. Autoimmunity reviews, 10 6:353-60, Apr 2011. URL: https://doi.org/10.1016/j.autrev.2010.11.008, doi:10.1016/j.autrev.2010.11.008. This article has 107 citations and is from a peer-reviewed journal.
(qi2024identificationofchallenging pages 2-4): Fei Qi, Yimeng Gao, and Hongzhong Jin. Identification of challenging diagnostic factors in livedoid vasculopathy: a retrospective study. Clinical, Cosmetic and Investigational Dermatology, 17:1747-1756, Aug 2024. URL: https://doi.org/10.2147/ccid.s466449, doi:10.2147/ccid.s466449. This article has 3 citations and is from a peer-reviewed journal.
(lee2020livedoidvasculopathyin pages 5-7): J. Lee and Soyun Cho. Livedoid vasculopathy in koreans: clinical features and response to rivaroxaban treatment. Journal of the European Academy of Dermatology and Venereology, Jan 2020. URL: https://doi.org/10.1111/jdv.16129, doi:10.1111/jdv.16129. This article has 19 citations and is from a domain leading peer-reviewed journal.
(evans2015successfultreatmentof pages 2-2): John M. Evans, J. Daniel Jensen, and Naveed Sami. Successful treatment of livedoid vasculopathy with rivaroxaban. JAAD Case Reports, 1:340-341, Nov 2015. URL: https://doi.org/10.1016/j.jdcr.2015.08.002, doi:10.1016/j.jdcr.2015.08.002. This article has 21 citations.
(criado2011livedoidvasculopathyas pages 2-3): Paulo Ricardo Criado, Evandro Ararigboia Rivitti, Mirian Nacagami Sotto, and Jozélio Freire de Carvalho. Livedoid vasculopathy as a coagulation disorder. Autoimmunity reviews, 10 6:353-60, Apr 2011. URL: https://doi.org/10.1016/j.autrev.2010.11.008, doi:10.1016/j.autrev.2010.11.008. This article has 107 citations and is from a peer-reviewed journal.
(gao2020plasminogenactivatorinhibitor‐1 pages 1-3): Yimeng Gao and Hongzhong Jin. Plasminogen activator inhibitor‐1: a potential etiological role in livedoid vasculopathy. International Wound Journal, 17:1902-1908, Oct 2020. URL: https://doi.org/10.1111/iwj.13480, doi:10.1111/iwj.13480. This article has 13 citations and is from a peer-reviewed journal.
(weishaupt2019characteristicsriskfactors pages 2-4): C. Weishaupt, A. Strölin, B. Kahle, A. Kreuter, S. W. Schneider, J. Gerss, M. Eveslage, A. Drabik, and T. Goerge. Characteristics, risk factors and treatment reality in livedoid vasculopathy – a multicentre analysis. Journal of the European Academy of Dermatology and Venereology, 33:1784-1791, Sep 2019. URL: https://doi.org/10.1111/jdv.15639, doi:10.1111/jdv.15639. This article has 71 citations and is from a domain leading peer-reviewed journal.
(agirbasli2011enhancedfunctionalstability pages 4-5): Mehmet Agirbasli, Mesut Eren, Fatih Eren, Sheila B. Murphy, Zehra A. Serdar, Dilek Seckin, Tuba Zara, M. Cem Mat, Cuyan Demirkesen, and Douglas E. Vaughan. Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy. Journal of Thrombosis and Thrombolysis, 32:59-63, Feb 2011. URL: https://doi.org/10.1007/s11239-011-0556-y, doi:10.1007/s11239-011-0556-y. This article has 36 citations and is from a peer-reviewed journal.
(agirbasli2011enhancedfunctionalstability pages 2-4): Mehmet Agirbasli, Mesut Eren, Fatih Eren, Sheila B. Murphy, Zehra A. Serdar, Dilek Seckin, Tuba Zara, M. Cem Mat, Cuyan Demirkesen, and Douglas E. Vaughan. Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy. Journal of Thrombosis and Thrombolysis, 32:59-63, Feb 2011. URL: https://doi.org/10.1007/s11239-011-0556-y, doi:10.1007/s11239-011-0556-y. This article has 36 citations and is from a peer-reviewed journal.
(leeolou2023livedoidvasculopathy pages 3-4): Melissa C. Leeolou, Kerri E Rieger, and Jennifer E Yeh. Livedoid vasculopathy. Dermatology Online Journal, Nov 2023. URL: https://doi.org/10.5070/d329562414, doi:10.5070/d329562414. This article has 4 citations and is from a peer-reviewed journal.
(weishaupt2019characteristicsriskfactors pages 1-2): C. Weishaupt, A. Strölin, B. Kahle, A. Kreuter, S. W. Schneider, J. Gerss, M. Eveslage, A. Drabik, and T. Goerge. Characteristics, risk factors and treatment reality in livedoid vasculopathy – a multicentre analysis. Journal of the European Academy of Dermatology and Venereology, 33:1784-1791, Sep 2019. URL: https://doi.org/10.1111/jdv.15639, doi:10.1111/jdv.15639. This article has 71 citations and is from a domain leading peer-reviewed journal.
(weishaupt2019characteristicsriskfactors pages 4-5): C. Weishaupt, A. Strölin, B. Kahle, A. Kreuter, S. W. Schneider, J. Gerss, M. Eveslage, A. Drabik, and T. Goerge. Characteristics, risk factors and treatment reality in livedoid vasculopathy – a multicentre analysis. Journal of the European Academy of Dermatology and Venereology, 33:1784-1791, Sep 2019. URL: https://doi.org/10.1111/jdv.15639, doi:10.1111/jdv.15639. This article has 71 citations and is from a domain leading peer-reviewed journal.
(palanisamy2023painmanagementoptions pages 3-3): Nageshwari Palanisamy, Justine Chinnappan, and Ghassan Bachuwa. Pain management options in a patient with livedoid vasculopathy and peripheral neuropathy. European Journal of Case Reports in Internal Medicine, Feb 2023. URL: https://doi.org/10.12890/2023_003727, doi:10.12890/2023_003727. This article has 3 citations.
(ramphall2022comparativeefficacyof pages 9-9): Shivana Ramphall, Swarnima Rijal, Vishakh Prakash, Heba Ekladios, Jiya Mulayamkuzhiyil Saju, Naishal Mandal, Nang I Kham, Rabia Shahid, Shaili S Naik, and Sathish Venugopal. Comparative efficacy of rivaroxaban and immunoglobulin therapy in the treatment of livedoid vasculopathy: a systematic review. Cureus, Aug 2022. URL: https://doi.org/10.7759/cureus.28485, doi:10.7759/cureus.28485. This article has 7 citations.
(NCT05878327 chunk 1): Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia. University of Zurich. 2013. ClinicalTrials.gov Identifier: NCT05878327
(NCT00975871 chunk 1): Correlation of Genetic Polymorphism and Livedo Vasculitis. National Taiwan University Hospital. 2007. ClinicalTrials.gov Identifier: NCT00975871